Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
3,367,000
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
382,073
-
Shares change
-
-660,582
-
Total reported value, excl. options
-
$1,230,314
-
Value change
-
-$1,793,165
-
Number of buys
-
6
-
Number of sells
-
-5
-
Price
-
$3.22
Significant Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q4 2024
21 filings reported holding CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value as of Q4 2024.
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 382,073 shares
of 3,367,000 outstanding shares and own 11% of the company stock.
Largest 10 shareholders include TYNDALL CAPITAL PARTNERS L P (164,777 shares), Siren, L.L.C. (116,155 shares), GEODE CAPITAL MANAGEMENT, LLC (31,820 shares), VANGUARD GROUP INC (23,490 shares), BlackRock, Inc. (16,797 shares), RENAISSANCE TECHNOLOGIES LLC (10,611 shares), UBS Group AG (9,667 shares), FMR LLC (4,740 shares), Tower Research Capital LLC (TRC) (2,441 shares), and MORGAN STANLEY (649 shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.